- Vaxil (VXL) has provided the final results of its research with Ben-Gurion University of the Negev
- The study achieved therapeutic success by prolonging the survival of mice with aggressive liver metastasis of colorectal cancer
- The results suggest that P-Esbp-doxorubicin is a promising targeted drug delivery system for the treatment of aggressive metastatic cancer
- Vaxil Bio is an immunotherapy biotech company focused on targeting prominent cancer markers and infectious diseases
- Vaxil (VXL) is up by 20 per cent and is currently trading at $0.09 per share
Vaxil (VXL) has provided the final results of its research with Ben-Gurion University of the Negev.
The company conducted an in vivo efficacy study for P-Esbp-doxorubicin, its licensed novel anti-cancer drug, which achieved therapeutic success by prolonging the survival of mice with aggressive liver metastasis of colorectal cancer.
The number of surviving mice at day 85 was 3/7 (43 per cent) for P-Esbp-doxorubicin, 1/6 (17 per cent) for free doxorubicin and 0/6 for P-doxorubicin and saline.
The results suggest that P-Esbp-doxorubicin is a promising targeted drug delivery system for the treatment of aggressive metastatic cancer.
The company is pursuing all necessary steps to initiate human clinical trials as soon as possible.
Vaxil Bio is an immunotherapy biotech company focused on targeting prominent cancer markers and infectious diseases.
Vaxil (VXL) is up by 20 per cent and is currently trading at $0.09 per share as of 11:31 am EST.
